

# TereoPneuma

## **FOR IMMEDIATE RELEASE**

Thursday, August 21, 2014

### **TereoPneuma Announces the ReDe Mask™ at Anesthesiology 2014**

SAN DIEGO, CA August 21, 2014 - TereoPneuma, Inc., a CA based company, today announced the first public presentation of its flagship product – the ReDe Mask™ – at Anesthesiology 2014 in New Orleans on October 11th-15th.

The ReDe Mask™ is a disposable, single use oxygen face mask and respiration monitor that simultaneously provides supplemental oxygen to patients while also detecting exhalation and displaying a visual signal of each exhalation. A three-color LED signaling system is used to indicate breathing events. A green indicator illuminates with each breath when the respiration rate is above 8 breaths per minute. A yellow indicator similarly illuminates with each breath when the respiration rate is 3 to 8 breaths per minute. A red indicator flashes rapidly when the breathing rate is less than 3 breaths per minute.

“We’re very pleased with the development behind the ReDe Mask™ and the outcome of the clinical evaluations we have completed this year. We look forward to announcing and demonstrating the ReDe Mask™ at Anesthesiology 2014.” said William J. Mazzei, MD, CEO of TereoPneuma, Inc.

The Anesthesiology meeting is convened annually by the American Society of Anesthesiologists (ASA) and is expected to have an attendance of 12,000 healthcare professionals both domestic and international including more than 3,000 physicians from 80 countries outside of the U.S. Anesthesiology 2014 provides current information on new products, services, and technologies useful in the practice of anesthesia.

### **About TereoPneuma**

TereoPneuma is a privately held medical device company in San Diego, CA whose mission is to develop novel high technology products in the field of anesthesia. TereoPneuma is Greek for “observe breathing”. TereoPneuma's first product - the ReDe Mask™ - is a disposable, single use oxygen face mask and respiration monitor that simultaneously provides supplemental oxygen to patients while also detecting exhalation and displaying a visual signal of each exhalation. Further, it provides a visual warning signal when no breath is detected for 7.5 seconds, and a more vivid visual warning signal when no breath is detected for 20 seconds. Detailed information on the Company is available at [www.tereopneuma.com](http://www.tereopneuma.com).

### **Contact:**

William J. Mazzei, MD, CEO  
TereoPneuma, Inc.  
[info@tereopneuma.com](mailto:info@tereopneuma.com)